Salem Radio Network News Monday, December 6, 2021


U.S. FDA approves BioMarin’s drug for a type of dwarfism

(Reuters) – The U.S. Food and Drug Administration (FDA) on Friday approved BioMarin Pharmaceutical Inc’s drug to improve growth in children with a type of dwarfism.

The approval, meant for children five years of age and older, comes months after Voxzogo became the first approved drug for achondroplasia in Europe. Achondroplasia is a genetic disorder affecting bone growth and leads to a short stature.

BioMarin’s drug works by reducing the activity of a gene that prevents normal bone growth in patients with the disorder.

The regulator has cleared the drug under the accelerated approval pathway, which requires the company to conduct a post-marketing study.

(Reporting by Amruta Khandekar; Editing by Aditya Soni)


Editorial Cartoons

View More »

Bob Gorrell
Tue, Nov 30, 2021